Axcelead Releases FDA NAMs Road Map Seminar on IND Strategy

Axcelead's recorded seminar with a former FDA senior manager surfaces practical guidance that non-clinical safety teams and regulatory affairs leads have been waiting for since the agency published its NAMs Road Map in April 2025: how to incorporate New Approach Methodologies into IND and NDA submissions during a transition period the FDA has set at three to five years.

The interview features Dr. McGovern, who contributed directly to drafting the NAMs Road Map, and addresses the submission uncertainties that have accumulated since the document's release. Central among them is whether mid-sized pharmaceutical companies and academic sponsors will face a disadvantage in IND review if they submit packages without NAMs data, a question with direct implications for resource allocation and study design timelines at organisations without established in vitro or in silico infrastructure.

The discussion covers the implementation status of in vitro, ex vivo, and in silico methods as replacements for conventional animal studies, including FDA's current acceptance position on in vitro cytokine release assays and humanised animals as substitutes for non-human primate studies. For regulatory leads managing biologics or immunology programmes, that acceptance status is a material data point for non-clinical package design ahead of IND filing.

The seminar was originally presented at the 53rd Annual Meeting of the Japanese Society of Toxicology and is available on-demand through October 2, 2026, subject to a registration form. The access window is fixed, which limits the planning horizon for teams intending to use the content to inform submission strategy or internal training.

Regulatory teams building non-clinical study plans for INDs expected within the next two to three years will need to reconcile existing animal-study commitments against the FDA's stated validation and adoption targets before the transition window closes.

Source: Axcelead via axcelead-us.com, 4 September 2026.